Overview
Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024
Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates
Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments
Outlook
Company anticipates substantial 4Q25 and annual revenue growth due to price normalization
Biofrontera expects enhanced margins from new Ameluz and RhodoLED royalty structure
Company sees potential FDA approval for Ameluz in new indications, expanding market opportunities
Result Drivers
ADVANCED PURCHASES - Q3 revenue decline attributed to advanced purchases in 2024 ahead of price increase
ASSET ACQUISITION - Purchase of Ameluz and RhodoLED assets expected to enhance margins and profitability
COMMERCIAL STRATEGY - Revamped sales strategy and customer segmentation proving effective
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $7 mln | $9 mln (2 Analysts) |
Q3 Net Income | -$6.60 mln | ||
Q3 Adjusted EBITDA | Miss | -$6 mln | -$2.60 mln (1 Analyst) |
Q3 Operating Expenses | $13.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Biofrontera Inc is $6.00, about 83.8% above its November 12 closing price of $0.97
Press Release: ID:nGNX557l71
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments